帕吉昔單抗
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | 葡萄球菌脂磷壁酸 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 595566-61-3  |
| ChemSpider | |
| UNII | |
| 化學資訊 | |
| 化學式 | C6462H9996N1728O2028S54 |
| 摩爾質量 | 146,072.36 g·mol−1 |
帕吉昔單抗（INN：Pagibaximab）是一種嵌合單株抗體，用於預防低出生體重嬰兒的葡萄球菌敗血症。截至2010年3月，該藥物尚在進行II/III期臨床試驗。[1][2]
參考資料
- ^ Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrobial Agents and Chemotherapy. July 2009, 53 (7): 2879–86. PMC 2704668
. PMID 19380597. doi:10.1128/AAC.01565-08.
- ^ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov
